Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma

被引：0
|
作者：
Chon, Hye Yeon [1 ,2 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Yongin Severance Hosp, Dept Internal Med, 363 Dongbaekjukjeon Daero, Yongin 16995, South Korea
来源：
KOREAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 83卷 / 02期
关键词：
ATEZOLIZUMAB;
D O I：
10.4166/kjg.2024.005
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：78 / 80
页数：3
相关论文
共 50 条
  • [41] Combining Checkpoint and Tyrosine Kinase Inhibitor in the Treatment of Renal Cell Carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (05) : 247 - 247
  • [42] Response to multi-targeted kinase inhibitor (MKI) after immune checkpoint inhibitor (ICI) in patients with hepatocellular carcinoma (HCC)
    Chng, S. S. Y.
    Tan, S. W. L.
    Lee, J. J. X.
    Choo, S. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues
    Yang, Shiye
    Liang, Huoqi
    Li, Xing
    Qian, Jiayi
    Ming, Zhibing
    HEPATOLOGY INTERNATIONAL, 2024, 18 (04) : 1336 - 1337
  • [44] Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection.
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ji, Yuan
    Ge, Ning-Ling
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma
    Hu, Yue
    Pan, Tao
    Cai, Xi
    He, Quan-Sheng
    Zheng, Yu-Bao
    Huang, Ming-Sheng
    Jiang, Zai-Bo
    Chen, Jun-Wei
    Wu, Chun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (04) : 1837 - +
  • [46] The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
    Ke, Qiao
    Xin, Fuli
    Fang, Huipeng
    Zeng, Yongyi
    Wang, Lei
    Liu, Jingfeng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [47] Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor
    Wang, Qian
    Zhang, Xingming
    Zhu, Qiyu
    Zeng, Hong
    Dai, Jindong
    Chen, Junru
    Zhao, Jinge
    Sun, Guangxi
    Liu, Zhenhua
    Zeng, Hao
    Shen, Pengfei
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, : 1433 - 1440
  • [48] Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC)
    Khorasanchi, Adam
    Kwok, Christopher
    Psutka, Sarah P.
    Hinkley, Megan
    Dason, Shawn
    Yang, Yuanquan
    Verschraegen, Claire F.
    Gross, Evan
    Orcutt, Delaney
    Yin, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Adverse events of sequential tyrosine kinase inhibitor following immune checkpoint inhibitor in advanced NSCLC patients
    Shimoda, Yukiko
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S482 - S483
  • [50] Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation
    Li Zhuang
    Hai-Bo Mou
    Lan-Fang Yu
    Heng-Kai Zhu
    Zhe Yang
    Qin Liao
    Shu-Sen Zheng
    Hepatobiliary & Pancreatic Diseases International, 2020, 19 (01) : 91 - 93
12345